Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

The purpose of this study is to find out the genetic and biochemical makeup of your neuroblastic tumor, which influences its aggressiveness and the suitable therapy. These research studies include surface marker analysis, cytogenetics, cancer genes,genome sequencing, tumor growth-related genes and tumor growth in test tubes. Your blood, marrow, and hematopoietic stem cell samples will also be tested for tumors or leukemia cells, and your serum tested for anti-tumor antibodies.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Neuroblastic tumors diagnosed in accordance with the International Neuroblastoma Staging System

⁃ OR

• Clinically suspected neuroblastic tumors.

⁃ PK DRAW INCLUSION CRITERIA (FOR PK DRAWS ONLY):

⁃ PK Draw Inclusion Criteria

• Patients who receive naxitamab as part of their standard of care

Locations
United States
New York
Memorial Sloan Kettering Cancer Center
RECRUITING
New York
Contact Information
Primary
Nai-Kong Cheung, M.D., Ph.D.
646-888-2313
Backup
Shakeel Modak, MD
212-639-7623
Time Frame
Start Date: 2000-09-26
Estimated Completion Date: 2026-09
Participants
Target number of participants: 2070
Treatments
1
Tumor and Marrow Markers
Sponsors
Collaborators: Washington University School of Medicine, Weill Medical College of Cornell University, Spanish National Cancer Center, University of Texas, St. Jude Children's Research Hospital, Southern Illinois University
Leads: Memorial Sloan Kettering Cancer Center

This content was sourced from clinicaltrials.gov

Similar Clinical Trials